Document is current
Any future updates will be listed below
-
Authors
Moors, Tim E.
Maat, Christina A.
Niedieker, Daniel
Mona, Daniel
Petersen, Dennis
Timmermans-Huisman, Evelien
Kole, Jeroen
El-Mashtoly, Samir F.
Spycher, Liz
Zago, Wagner
Barbour, Robin
Mundigl, Olaf
Kaluza, Klaus
Huber, Sylwia
Hug, Melanie N.
Kremer, Thomas
Ritter, Mirko
Dziadek, Sebastian
Geurts, Jeroen J. G.
Gerwert, Klaus
Britschgi, Markus
van de Berg, Wilma D. J. https://orcid.org/0000-0002-6175-5357
-
Funding
Funding for this research was provided by:
Roche
- License Information
-
More Information
Article History
Received: 21 February 2021
Revised: 11 May 2021
Accepted: 12 May 2021
First Online: 11 June 2021
Declarations
:
: The authors declare no competing interests. DM, LS, OM, KK, SH, MH, TK, MR, SD, and MB are or were full-time employees of Roche/F. Hoffmann–La Roche Ltd, and they may additionally hold Roche stock/stock options. WZ and RB are full-time employees of Prothena Biosciences Inc.
: Post-mortem human brain tissue from clinically diagnosed and neuropathologically verified donors with advanced PD as well as non-demented controls was collected by the Netherlands Brain Bank (). In compliance with all local ethical and legal guidelines, informed consent for brain autopsy and the use of brain tissue and clinical information for scientific research was given by either the donor or the next of kin. A reference to the published Code of Conduct for brain banking of BrainNet Europe (where NBB participated in) is provided in the text []. The procedures of the Netherlands Brain Bank (Amsterdam, The Netherlands) were approved by the Institutional Review Board and Medical Ethical Board (METC) from the VU University Medical Center (VUmc), Amsterdam.
